ArticleProstate cancer and prostatic diseases2020
Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.
Article in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Genomic-Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence.Cancer medicine · 2026Pooled it
- Artificial Intelligence impact on decision-making regarding short-term ADT with prostate radiotherapy: ASTuTE clinical trial interim results.Clinical and translational radiation oncology · 2026Article
- Article
- Active surveillance could apply to one-quarter of Korean prostate cancer cases: Insights from a 27,075-patient cohort.Prostate international · 2026Article
- A Pilot Study ofThe Prostate · 2026Article
- Prostate Cancer Biomarkers with a Focus on Galectin-3: Emerging Clinical and Therapeutic Implications.Current oncology (Toronto, Ont.) · 2026Review
- PSA Density and PIRADS 5 Lesions as Key Determinants of Upstaging After Radical Prostatectomy.Cancers · 2026Article
- Impact of a Precision Medicine Navigator on Genomic Test Utilization in Black Patients With Prostate Cancer.JCO oncology practice · 2026Article
- Review
- Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes.European urology open science · 2026Article
- Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance.The Prostate · 2025Article
- Identifying the best candidate for focal therapy: a comprehensive review.Prostate cancer and prostatic diseases · 2025Review
- Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment.International journal of molecular sciences · 2025Review
- Systems biology successes and areas for opportunity in prostate cancer.Endocrine-related cancer · 2025Review
- Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.Prostate cancer and prostatic diseases · 2025Observational
- Assessing the Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from the MAST Trial.European urology focus · 2025Article
- Clinical validation of a biopsy-based six-gene signature prognostic for aggressive prostate cancer.BJUI compass · 2025Article
- Integration of Genomic Tests in Prostate Cancer Care: Implications for Clinical Practice and Patient Outcomes.Current issues in molecular biology · 2024Review
- Prostate cancer theragnostics biomarkers: An update.Investigative and clinical urology · 2024Review
- Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to validate Decipher to predict adverse pathology (AP) at radical prostatectomy (RP) in men with National Comprehensive Cancer Network (NCCN) favorable-intermediate risk (F-IR) prostate cancer (PCa), and to better select F-IR candidates for active surveillance (AS).
methodsIn all, 647 patients diagnosed with NCCN very low/low risk (VL/LR) or F-IR prostate cancer were identified from a multi-institutional PCa biopsy database; all underwent RP with complete postoperative clinicopathological information and Decipher genomic risk scores. The performance of all risk assessment tools was evaluated using logistic regression model for the endpoint of AP, defined as grade group 3-5, pT3b or higher, or lymph node invasion.
resultsThe median age was 61 years (interquartile range 56-66) for 220 patients with NCCN F-IR disease, 53% classified as low-risk by Cancer of the Prostate Risk Assessment (CAPRA 0-2) and 47% as intermediate-risk (CAPRA 3-5). Decipher classified 79%, 13% and 8% of men as low-, intermediate- and high-risk with 13%, 10%, and 41% rate of AP, respectively. Decipher was an independent predictor of AP with an odds ratio of 1.34 per 0.1 unit increased (p value = 0.002) and remained significant when adjusting by CAPRA. Notably, F-IR with Decipher low or intermediate score did not associate with significantly higher odds of AP compared to VL/LR.
conclusionsNCCN risk groups, including F-IR, are highly heterogeneous and should be replaced with multivariable risk-stratification. In particular, incorporating Decipher may be useful for safely expanding the use of AS in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.